{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:07:50Z","timestamp":1777662470556,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ensign Endowment for Gynecologic Cancer Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ygyno.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:01:04Z","timestamp":1558634464000},"page":"169-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8701","authenticated-orcid":false,"given":"Koji","family":"Matsuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Mandelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-3577","authenticated-orcid":false,"given":"Hiroko","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2254-3378","authenticated-orcid":false,"given":"Kosuke","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco M.","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda D.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.05.014_bb0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2014.10.029","article-title":"Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis","volume":"136","author":"Molina-Montes","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2007.11.9081","article-title":"Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study","volume":"26","author":"Schaapveld","year":"2008","journal-title":"J Clin Oncol l"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0020","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(12)60442-5","article-title":"Contemporary management of endometrial cancer","volume":"379","author":"Wright","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0030","first-page":"378","article-title":"Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention","volume":"67","author":"Picon-Ruiz","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0035","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10\u202fyears versus stopping at 5\u202fyears after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0045","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0050","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2018.10.019","article-title":"Cancer susceptibility gene mutations in type I and II endometrial cancer","volume":"152","author":"Long","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0060","series-title":"International Population Reports","author":"An Aging World","year":"2015"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0065","author":"Health, United States"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","article-title":"American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004","volume":"23","author":"Winer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0085","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/jnci\/djq345","article-title":"Breast cancer incidence and hormone replacement therapy in Canada","volume":"102","author":"De","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2458-10-228","article-title":"Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California","volume":"10","author":"Ereman","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0100","author":"National Cancer Registrars Association"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0105","doi-asserted-by":"crossref","first-page":"28757","DOI":"10.18632\/oncotarget.25550","article-title":"Trends and outcomes of women with synchronous endometrial and ovarian cancer","volume":"9","author":"Matsuo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/AOG.0000000000002142","article-title":"Risk of subsequent ovarian cancer after ovarian conservation in young women with stage I endometrioid endometrial cancer","volume":"130","author":"Matsuo","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050714","article-title":"Decreasing trends of secondary primary colorectal cancer among women with uterine cancer","author":"Matsuo","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0120","unstructured":"Italian cancer figures, report 2013: multiple tumours. Epidemiol. Prev. 2104;37:1-152."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0125","series-title":"AJCC Cancer Staging Manual","year":"2010"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0130","author":"National Death Index"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0140","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2012.41.6701","article-title":"Comparative effectiveness research in oncology methodology: observational data","volume":"30","author":"Hershman","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Yao","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0150","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ejca.2008.11.030","article-title":"Multiple tumours in survival estimates","volume":"45","author":"Rosso","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study","volume":"97","author":"Swerdlow","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0165","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0175","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0180","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/gim.2017.118","article-title":"Trends in utilization and costs of BRCA testing among women aged 18\u201364\u202fyears in the United States, 2003\u20132014","volume":"20","author":"Chen","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0190","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/ijc.28537","article-title":"The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer\u2013a population-based data linkage study","volume":"134","author":"Obermair","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gore.2018.10.003","article-title":"Hysterectomy at the time of risk-reducing surgery in BRCA carriers","volume":"26","author":"Nair","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0205","doi-asserted-by":"crossref","unstructured":"Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med l995;332:1589-93.","DOI":"10.1056\/NEJM199506153322401"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0215","doi-asserted-by":"crossref","unstructured":"Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst. Rev. l2015: CD007245.","DOI":"10.1002\/14651858.CD007245.pub3"},{"key":"10.1016\/j.ygyno.2019.05.014_bb0225","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/bcr3206","article-title":"Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries","volume":"14","author":"Jones","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2016.12.024","article-title":"Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma","volume":"144","author":"Pierce","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.014_bb0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2016.11.042","article-title":"Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma","volume":"144","author":"Matsuo","year":"2017","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:42:00Z","timestamp":1758771720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819312582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0090825819312582"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}